INTRODUCTION

Aortic stenosis (AS) is a common valve disease in elderly people and its prevalence increases 10% after 80 years old[1]. It is a degenerative and an atherosclerotic-like process that involves both vessels and aortic valve[2,3]. Pathologically increased calcium and collagen ratio leads to arterial stiffness and AS [4]. When the aorta becomes stiffer, the elastic capacity decreases and aortic pulse wave velocity (PWV) increases. It is known that elastic recoil of the aorta maintains the perfusion pressure of the tissues during diastole after aortic valve closure. The velocity of pressure wave is affected by elastic properties of comprised vessel. Increased aortic stiffness leads to increase in PWV and cardiac afterload[5,6]. The correlation of PWV and cardiovascular disease also has been well established[7,8].

On the other hand, transcatheter aortic valve implantation (TAVI) has become the main therapeutic approach for surgical high-risk or inoperable patients with symptomatic severe AS[10,11]. In literature, sutureless implantation and incomplete circumferential apposition of the valve at aortic annulus are regarded as the main causes of paravalvular aortic regurgitation (PAR). It is known that mild PAR after TAVI procedure has no adverse effects on cardiovascular outcomes [12,13]. However, in some recent studies, the clinical significance of mild PAR has been evaluated and suggested that it can be predictor of clinical outcomes[13,14]. In our study, we aimed to investigate the interaction of aortic PWV and mild PAR and their effects on the functional status of patients after transcatheter aortic valve implantation (TAVI).

METHODS

A total of 109 consecutive patients with symptomatic severe aortic stenosis were enrolled prospectively. After TAVI procedure, they were divided in to three groups according to PAR and PWV measurements. Patients without PAR were defined as the NonePAR group (n=60), patients with mild PAR and normal PWV were defined as the MildPAR-nPWV group (n=23), and patients with mild PAR and high PWV were defined as the MildPAR-hPWV group (n=26).

RESULTS

Compared with other groups, the MildPAR-hPWV group was older (P<0.001), hypertensive (P=0.015), and had a higher pulse pressure (P=0.018). In addition to PWV, this group had lower aortic regurgitation index (ARI) (P=0.010) and higher rate of New York Heart Association (NYHA) class II (at least) patients (P<0.001) in 30-day follow-up period. On multivariate regression analysis, the MildPAR-hPWV group (odds ratio=1.364, 95% confidence interval 1.221-1.843; P=0.011) as well as N-terminal-pro-brain natriuretic peptide levels and ARI were independently related with 30-day functional NYHA classification. However, NonePAR or MildPAR-nPWV group was not an independent predictor of early functional status.

CONCLUSION

It was concluded that high PWV may adversely affect early functional status in patients with mild PAR in contrast to normal values following TAVI.

Keywords: Transcatheter Aortic Valve Replacement. Aortic Valve Insufficiency. Pulse Wave Analysis. Blood Pressure. Reference Values. Aortic Valve Stenosis. Regression Analysis.

INTRODUCTION

The Influence of Aortic Pulse Wave Velocity on Short-Term Functional Capacity in Patients with Mild Paravalvular Regurgitation Following Transcatheter Aortic Valve Implantation

Ibrahim Halil Kurt1, MD; Ömer Şen1, MD; Mehmet Kuçükosmanoğlu1, MD; Fatma Özge Salkın1, MD; Örsan Deniz Urgun1, MD; Şeyda Şahin1, MD; Salih Çolak1, MD; Salih Kılıç1, MD

Abstract

Introduction: Recently, the clinical significance of mild paravalvular aortic regurgitation (PAR) has been evaluated and suggested that it can be predictor of clinical outcomes. In our study, we aimed to investigate the interaction of aortic pulse wave velocity (PWV) and mild PAR and their effects on the functional status of patients after transcatheter aortic valve implantation (TAVI).

Methods: A total of 109 consecutive patients with symptomatic severe aortic stenosis were enrolled prospectively. After TAVI procedure, they were divided in to three groups according to PAR and PWV measurements. Patients without PAR were defined as the NonePAR group (n=60), patients with mild PAR and normal PWV were defined as the MildPAR-nPWV group (n=23), and patients with mild PAR and high PWV were defined as the MildPAR-hPWV group (n=26).

Results: Compared with other groups, the MildPAR-hPWV group was older (P<0.001), hypertensive (P=0.015), and had a higher pulse pressure (P=0.018). In addition to PWV, this group had lower aortic regurgitation index (ARI) (P=0.010) and higher rate of New York Heart Association (NYHA) class II (at least) patients (P<0.001) in 30-day follow-up period. On multivariate regression analysis, the MildPAR-hPWV group (odds ratio=1.364, 95% confidence interval 1.221-1.843; P=0.011) as well as N-terminal-pro-brain natriuretic peptide levels and ARI were independently related with 30-day functional NYHA classification. However, NonePAR or MildPAR-nPWV group was not an independent predictor of early functional status.

Conclusion: It was concluded that high PWV may adversely affect early functional status in patients with mild PAR in contrast to normal values following TAVI.

Keywords: Transcatheter Aortic Valve Replacement. Aortic Valve Insufficiency. Pulse Wave Analysis. Blood Pressure. Reference Values. Aortic Valve Stenosis. Regression Analysis.
Kurt IH, et al. - Aortic Pulse Wave Velocity in TAVI

METHODS
Patient Population

Between May 2016 and June 2018, 188 consecutive patients with symptomatic severe AS were evaluated by a heart team, and 129 of them were enrolled in the study prospectively. Among these, 20 patients were excluded from the study due to comorbidities that have significant effect on PWV measurement or functional status (five patients had more than mild aortic regurgitation [AR], five patients had left ventricular ejection fraction [LVEF] < 45%, one patient had disabling stroke, four patients had chronic kidney disease, three patients had thoracic or abdominal aneurysm, and two patients had severe pulmonary disease), remaining 109 patients. The Ethics Committee approved the study protocol, and informed consent was obtained from all patients.

The patients were evaluated one day before the TAVI procedure and at the first month after it. Before TAVI, full clinical and medical history, physical examination including height and weight, and routine blood samples including N-terminal pro-brain natriuretic peptide (NT-proBNP) were collected. In patients eligible for TAVI, all medications that would affect the vascular tone, caffeine, and alcohol were withheld at least 24 hours before the measurement. To prevent inter-measurement variability, a single observer, unaware of patient data, received all measurements. At least three consecutive measurements were performed. Arterial stiffness was measured from the right brachial region after resting for at least 15 minutes, in a silent room, at appropriate room temperature (22-25 °C) to minimize the artefacts, in complete basal resting condition, in supine position, and using a Mobil-O-Graph® ARC solver algorithm (IEM GmbH, Stolberg, Germany). This measurement algorithm gives us simultaneous assessment of AS parameters, such as PWV and Augmentation Index\(^{[16,17]}\). PWV calculation includes dynamically measured results and individual-related values. Aortic pressure, stroke volume, flow, and pressure curves are evaluated simultaneously to establish the association with individual PWV (Figure 1). Before and after the first month of procedure, PWV values were assessed with ARC solver algorithm. According to the Reference Values for Arterial Stiffness Collaboration, we used 10.5 m/sn as the cut-off value for PWV in our study\(^{[7]}\). However, patients who were older than 70 years old, had 10.6 m/sn median PWV value in their data.

Echocardiography

All patients underwent transthoracic echocardiography (TTE) before, early after, and one month after TAVI procedure.
After heparin injection for maintaining effective anticoagulation, temporary pacemaker lead and pigtail catheter were placed. We measured aortic and left ventricular, systolic, and diastolic pressures before valve implantation. We used self-expandable bioprosthetic valves (CoreValve™ [Medronic Inc; Minneapolis, Minnesota, United States of America] or Portico™ [St. Jude Medical, Minneapolis, Minnesota, United States of America]) for all patients.

At least 10 minutes after the valve implantation or post-dilatation, we measured pressures again within the heart rate between 60-80 beat/min. We also used aortic regurgitation index (ARI) for objective and quantitative assessment of PAR during TAVI procedure. ARI is a ratio of difference between diastolic pressures of aorta and left ventricular to systolic pressure of aorta. It has been validated before and has an inverse correlation with PAR after TAVI. In addition, it has shown that cut-off value of ARI 25 had 95%-100% negative predictive value for more than mild PAR[12,17].

Statistical Analysis

Statistical analysis was performed using SPSS Inc. Released 2008, SPSS Statistics for Windows, Version 17.0, Chicago: SPSS.
backward conditional logistic regression analysis was used to obtain the independent predictors of NYHA functional status. Two-tailed $P$-value < 0.05 was considered as statistically significant.

**RESULTS**

The mean age of the study group was 77.6±5.1 years; 62 (55.2%) patients were female, and 47 (44.8%) were male. MildPAR-hPWV group was older and the number of patients with hypertension in this group was higher than in other groups (Table 1). The other baseline characteristics, including the Society of Thoracic Surgeons score ($P$=0.618), were similar within groups (Table 1).

### Table 1. Patients’ baseline characteristics.

| Variables                              | NonePAR group (n=60) | MildPAR-nPWV group (n=23) | MildPAR-hPWV group (n=26) | $P$-value (ANOVA) |
|----------------------------------------|----------------------|---------------------------|---------------------------|-------------------|
| Age (years)                            | 75.5±4.5$^a$         | 76.8±4.5$^bc$             | 81.1±5.1                  | < 0.001           |
| Sex (male), n (%)*                     | 23 (38.3)            | 11 (48.8)                 | 13 (50)                   | 0.966             |
| BMI (kg/m²)                            | 27±5.6               | 27±4.9                    | 26±6.2                    | 0.904             |
| Hypertension, n (%)*                   | 25 (41.7)$^c$        | 7 (30.4)$^d$              | 18 (69.2)                 | 0.015             |
| DM, n (%)*                             | 15 (25)              | 6 (26.1)                  | 8 (30.8)                  | 0.417             |
| Smoking, n (%)*                        | 10 (16.7)            | 5 (21.7)                  | 7 (26.9)                  | 0.548             |
| Previous CABG, n (%)*                  | 14 (23.3)            | 6 (26.1)                  | 8 (30.8)                  | 0.859             |
| Coronary artery disease, n (%)*        | 32 (53.3)            | 10 (43.5)                 | 11 (42.3)                 | 0.341             |
| AF, n (%)*                             | 12 (20)              | 6 (23)                    | 6 (26)                    | 0.234             |
| STS score (%)                          | 11.2±2.7             | 11.8±2.9                  | 11.15±2.1                 | 0.618             |
| Medication, n (%)*                     | 43 (71.7)            | 18 (69.2)                 | 17 (74)                   | 0.623             |
| Aspirin                                | 16 (26.6)            | 8 (31)                    | 7 (30)                    | 0.186             |
| Statin                                 | 28 (46.6)            | 14 (54)                   | 12 (52.1)                 | 0.324             |
| β-blocker                              | 16 (26.6)            | 9 (34.6)                  | 7 (30)                    | 0.254             |
| WBC count (´1000/µl)                   | 13.1±3.98            | 12.8±4.78                 | 13.2±3.72                 | 0.266             |
| Hemoglobin (mg/dl)                     | 11.1±1.62            | 10.9±1.85                 | 11±1.36                   | 0.522             |
| Platelet count (´109/l)                | 188±68               | 176±52                    | 196±44                    | 0.346             |
| Creatinine (mg/dl)                     | 0.91±0.24            | 0.86±0.20                 | 0.88±0.36                 | 0.286             |
| Total cholesterol (mg/dl)              | 192.2±28.6           | 186.8±33                  | 189.3±25                  | 0.428             |
| HDL-C (mg/dl)                          | 39.6±8.4             | 40.2±9.9                  | 38.7±7.8                  | 0.312             |
| LDL-C (mg/dl)                          | 127±35.5             | 132±29                    | 125±41                    | 0.218             |

$X^2$ for significant $P$-values ($P<0.05$) indicated in boldface.

Significant $P$-values ($P<0.05$) are indicated in boldface.

ACE-I/ARB=angiotensin converting enzyme inhibitor/angiotensin II receptor blocker; AF=atrial fibrillation; ANOVA=analysis of variance; BMI=body mass index; CABG=coronary artery bypass grafting; DM=diabetes mellitus; HDL-C=high-density lipoprotein cholesterol; LDL-C=low-density lipoprotein cholesterol; MildPAR-hPWV=mild paravalvular aortic regurgitation with high pulse wave velocity; MildPAR-nPWV=mild paravalvular aortic regurgitation with normal pulse wave velocity; NonePAR=no paravalvular aortic regurgitation; STS=Society of Thoracic Surgeons; WBC=white blood cell.
The patients’ pre-and post-TAVI echocardiographic measurements including aortic valve area, aortic gradients, more than mild mitral and AR degree, left ventricular mass index, and LVEF were found similar within groups. Pre-TAVI, MildPAR-hPWV group had significant pulse pressure (PP) value (NonePAR 51.5±12.9 vs. MildPAR-nPWV 50.8±12.6 vs. MildPAR-hPWV 60.2±8.9; P=0.018), in contrast to post-TAVI values (P=0.067). MildPAR-hPWV group also had lower ARI than other groups (NonePAR 31.8±4.1 vs. MildPAR-nPWV 32.9±3.5 vs. MildPAR-hPWV 29.3±4.7; P=0.010). Distributions of ARI within groups are shown in Figure 2. Totally, 22 (20.2%) patients needed permanent pacemaker implantation due to heart block after TAVI, however there was no significant difference within groups (P=0.654). In addition, MildPAR-hPWV group also had a higher rate of NYHA class II (at least) patients (NonePAR 21.7% vs. MildPAR-nPWV 17.4% vs. MildPAR-hPWV 64.4%; P<0.001) in a 30-day follow-up period. Distribution of NYHA class > II within groups is shown in Figure 3. First-month NT-proBNP levels (P=0.009) were also found higher in the MildPAR-hPWV group than in the other groups (Table 2).

On multivariate regression analysis, the MildAR-hPWV group (odds ratio=1.364, 95% confidence interval 1.221-1.843; P=0.011) as well as NT-proBNP levels and ARI were independently associated with 30-day functional NYHA classification. However, NonePAR or MildPAR-nPWV group was not an independent predictor of early functional status.

**DISCUSSION**

In our study, we have shown that patients who had high PWV together with mild PAR following TAVI procedure had worse early functional status as compared with none PAR patients or mild PAR patients with normal PWV. To the best of our knowledge, this is the first study to investigate the clinical significance of mild PAR subgroups after TAVI procedure. We also demonstrated that the NT-proBNP levels and hemodynamic ARI were independently associated with the early functional status in these patients.

There are various cardiovascular risk factors such as age, hypertension, diabetes mellitus, and chronic kidney disease contributing to aortic stiffness\[7-9\]. It is also known that aortic stiffness is a good predictor of concomitant cardiovascular diseases and can be measured by non-invasive PWV measurements\[8,16,17\]. Accordingly, MildPAR-hPWV group was older and more likely had hypertensive baseline characteristic than the other groups, which was confirmed by these studies\[7-9\]. These patients’ PWV values were higher than the reported reference values, in addition to age and hypertension-related increase\[3\]. Also, the best-known effect of increased aortic stiffness is early aortic pulse reflection, which causes an increase in PP due to an increase in systolic blood pressure, and a decrease in diastolic blood pressure. In the present study, patients with high PWV had higher PP, consistent with previous studies\[21\].
clinical outcomes\textsuperscript{[13,14]}. Furthermore, the PARTNER trial has found independent association between mild PAR and late mortality after TAVI\textsuperscript{[14]}. In addition, the correlation between cardiovascular morbidity and mortality with PWV has been well established before\textsuperscript{[8,9]}. Taken together, degenerative elastic properties of aorta, which reflects as high PWV, may contribute to clinical deterioration of the patients with mild PAR, as described in our study.

In the present study, 53\% of the patients had none, 43\% of the patients had mild, and 4,3\% of the patients had more than mild PAR, consistent with previous studies\textsuperscript{[22-24]}. It is known that residual more than mild PAR has unfavourable prognostic affects and increases the risk of morbidity and mortality after TAVI\textsuperscript{[25,26]}. However, in some studies, the clinical significance of mild PAR has been evaluated and suggested that it can be a predictor of clinical outcomes\textsuperscript{[13,14]}. Furthermore, the PARTNER trial has found independent association between mild PAR and late mortality after TAVI\textsuperscript{[14]}. In addition, the correlation between cardiovascular morbidity and mortality with PWV has been well established before\textsuperscript{[8,9]}. Taken together, degenerative elastic properties of aorta, which reflects as high PWV, may contribute to clinical deterioration of the patients with mild PAR, as described in our study.

### Table 2. Patients’ clinic, hemodynamic, and echocardiographic characteristics.

| Variables                  | NonePAR group (n=60) | MildPAR-nPWV group (n=23) | MildPAR-hPWV group (n=26) | P-value (ANOVA) |
|----------------------------|----------------------|---------------------------|---------------------------|----------------|
| Pre-TAVI SBP (mmHg)        | 121±16               | 119±14                    | 123.1±13.4                | 0.765          |
| Post-TAVI SBP (mmHg)       | 119±18               | 122±21                    | 121±24                    | 0.767          |
| Pre-TAVI DBP (mmHg)        | 67.5±8.3             | 67±6.8                    | 64.3±8.9                  | 0.333          |
| Post-TAVI DBP (mmHg)       | 68.4±8.2             | 68.2±8.6                  | 66±8.2                    | 0.346          |
| Pre-TAVI MAP (mmHg)        | 91±9.2               | 88.7±8.2                  | 85.6±10.4                 | 0.112          |
| Post-TAVI MAP (mmHg)       | 91.7±12              | 92.2±13                   | 86.9±11                   | 0.230          |
| Pre-TAVI PP (mmHg)         | 51.5±129.9\textsuperscript{a} | 50.8±12.6\textsuperscript{b} | 60.2±8.9                  | 0.018          |
| Post-TAVI PP (mmHg)        | 50.8±12.7            | 54.8±15.5                 | 59.6±15.6                 | 0.067          |
| Pre-TAVI pulse (beat/min)  | 72±13                | 68±9                      | 68±15                     | 0.369          |
| Post-TAVI pulse (beat/min) | 74±16                | 69±12                     | 76±11                     | 0.286          |
| Pre-TAVI AVA (cm\textsuperscript{2}) | 0.75±0.9             | 0.74±0.07                 | 0.76±0.11                 | 0.891          |
| Post-TAVI AVA (cm\textsuperscript{2}) | 2.08±0.27            | 2.11±0.18                 | 2.14±1.9                  | 0.842          |
| Pre-TAVI AVPG (mmHg)       | 77±11                | 76±10                     | 79±10.5                   | 0.480          |
| Post-TAVI AVPG (mmHg)      | 11±4                 | 14±3                      | 10±4                      | 0.384          |
| Pre-TAVI AVMG (mmHg)       | 47.1±6.2             | 46.5±5.5                  | 48.5±7                    | 0.344          |
| Post-TAVI AVMG (mmHg)      | 5±3                  | 7±4                       | 6±3                       | 0.524          |
| LVEF (%)                   | 55±10.4              | 54±9.6                    | 55±7.6                    | 0.756          |
| LVMi (g/m\textsuperscript{2}) | 122.6±26              | 121.8±31                  | 123±24                    | 0.652          |
| Post-TAVI NYHA class, n(%) | 13 (21.7)            | 4 (17.4)                  | 17 (64.4)                 | < 0.001        |
| Permanent pacemaker implantation, n (%) | 11 (19)              | 5 (21.7)                  | 6 (23.1)                  | 0.654          |
| Pre-TAVI AR > Mild, n (%)  | 7 (11.6)             | 4 (15.3)                  | 3 (13)                    | 0.284          |
| AR index                   | 31.8±4.1\textsuperscript{c} | 32.9±3.5\textsuperscript{d} | 29.3±4.7                 | 0.010          |
| Pre-TAVI PWV (m/sec)       | 10.2±1.7             | 9.7±1.8                   | 12.2±1.2                  | < 0.001        |
| Post-TAVI PWV (m/sec)      | 10±1.7               | 9.6±1.9                   | 12.3±1.4                  | < 0.001        |
| NT-proBNP (pg/ml)          | 613±448\textsuperscript{e} | 572±414\textsuperscript{f} | 913±438                  | 0.009          |

Significant P-values (P<0.05) are indicated in boldface.
\textsuperscript{a}P=0.070 vs. MildPAR-hPWV group; \textsuperscript{b}P=0.023 vs. MildPAR-hPWV group
\textsuperscript{c}P=0.046 vs. MildPAR-hPWV group; \textsuperscript{d}P=0.012 vs. MildPAR-hPWV group
\textsuperscript{e}P=0.015 vs. MildPAR-hPWV group; \textsuperscript{f}P=0.026 vs. MildPAR-hPWV group

ANOVA=analysis of variance; AR=aortic regurgitation; AVA=aortic valve area; AVMG=aortic valve mean gradient; AVPG=aortic valve peak gradient; DBP=diastolic blood pressure; LVEF=left ventricular ejection fraction; LVMi=left ventricular mass index; MAP=mean arterial pressure; MildPAR-hPWV=mild paravalvular aortic regurgitation with high pulse wave velocity; MildPAR-nPWV=mild paravalvular aortic regurgitation with normal pulse wave velocity; NonePAR=no paravalvular aortic regurgitation; NT-proBNP=N-terminal pro-brain natriuretic peptide; NYHA=New York Heart Association; PP=pulse pressure; PWV=pulse wave velocity; SBP=systolic blood pressure; TAVI=transcatheter aortic valve implantation
ARI is a reproducible and quantitative hemodynamic AR degree measurement method used during TAVI procedure, which has been validated before with a high accuracy rate[13,15]. We know that impairment of ventricular-vascular coupling by increased aortic stiffness provides additional work to the heart[5]. As a result, ARI value is decreased, due to increased left ventricle diastolic pressure and aortic systolic pressure with decreased aortic diastolic pressure. In our study, we found lower ARI value in patients with high PWV, supporting this hypothesis.

NT-proBNP level increase by stretching of the myocardium due to pressure or volume overload, and it is a known strong predictive value of adverse outcomes in patients with cardiovascular diseases[27]. Different severity of PAR occurring as a complication after TAVI changes the pressure overload to volume overload and increases the mortality rate[25,26]. Accordingly, increased afterload and left ventricular end diastolic pressure due to high PWV may contribute to higher NT-proBNP levels and clinical worsening, as we found higher rate of NYHA class II patients (at least) in this group, supports this hypothesis.

Limitations

First of all, this is a single-centre study including small number of patients. Secondly, we used TTE instead of TEE during the procedure for PAR grading because all procedures were performed under mild sedation. Finally, patients with mild AR and high PWV had significantly more hypertension than patients with normal PWV and were older as well. These two circumstances might affect the functional status of patients in the first-month follow-up.

CONCLUSION

In the present study, we demonstrated that impairment of aortic elastic properties, which reflects as high PWV, might contribute to early clinical deterioration especially in patients with mild PAR after transfemoral TAVI procedure. These results are also suggesting that the impact of mild PAR on early functional status may be depending on underlying baseline PWV. However, this is the first study to find this association and need to be supported by larger future trials.

REFERENCES

1. Rashedi N, Otto CM. Aortic stenosis: changing disease concepts. J Cardiovasc Ultrasound. 2015;23(2):59-69. doi:10.4250/jcu.2015.23.2.59.
2. Poggiianti E, Venneti L, Chubuchny V, Jambrik Z, Baroncini LA, Picano E. Aortic valve sclerosis is associated with systemic endothelial dysfunction. J Am Coll Cardiol. 2003;41(1):136-41. doi:10.1016/s0735-1097(02)02622-0.
3. Chandra HR, Goldstein JA, Choudhary N, O'Neill CS, George PB, Gangasari SR, et al. Adverse outcome in aortic sclerosis is associated with coronary artery disease and inflammation. J Am Coll Cardiol. 2004;43(2):169-75. doi:10.1016/j.jacc.2003.08.036.
4. Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J. 2006;27(21):2588-605. doi:10.1093/eurheartj/ehl254.
5. Asanoi H, Sasayama S, Kameyama T. Ventriculoarterial coupling in normal and failing heart in humans. Circ Res. 1989;65(2):483-93. Erratum in: Circ Res 1990;66(4):1170. doi:10.1161/01.res.65.2.483.
6. O’Rourke MF. How stiffening of the aorta and elastic arteries leads to compromised coronary flow. Heart. 2008;94(6):690-1. doi:10.1136/hrt.2007.134791.
7. Reference Values for Arterial Stiffness’ Collaboration. Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: establishing normal and reference values. Eur Heart J. 2010;31(19):2338-50. doi:10.1093/eurheartj/eth415.
8. Millasseau SC, Stewart AD, Patel SJ, Redwood SR, Chowienczyk PJ. Evaluation of carotid-femoral pulse wave velocity: influence of timing algorithm and heart rate. Hypertension. 2005;45(2):222-6. doi:10.1161/01.hyp.0000154229.97341.d2.
9. Cecelja M, Chowienczyk P. Dissociation of aortic pulse wave velocity with risk factors for cardiovascular disease other than hypertension: a systematic review. Hypertension. 2009;54(6):1328-36. doi:10.1161/HYPERTENSIONAHA.109.137653.
10. Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med. 2011;364(23):2187-98. doi:10.1056/NEJMoa1103510.
11. Gurvitch R, Wood DA, Tay EL, Leipsic J, Ye J, Lichtenstein SV.
et al. Transcatheter aortic valve implantation: durability of clinical and hemodynamic outcomes beyond 3 years in a large patient cohort. Circulation. 2010;122(13):1319-27. doi:10.1161/CIRCULATIONAHA.110.948877.

12. Pibarot P, Hahn RT, Weissman NJ, Monaghan MJ. Assessment of paravalvular regurgitation following TAVR: a proposal of unifying grading scheme. JACC Cardiovasc Imaging. 2015;8(3):340-60. doi:10.1016/j.jcmg.2015.01.008.

13. Athappan G, Patvardhan E, Tuzcu EM, Svensson LG, Lemos PA, Fracarro C, et al. Incidence, predictors, and outcomes of aortic regurgitation after transcatheter aortic valve replacement: meta-analysis and systematic review of literature. J Am Coll Cardiol. 2013;61(15):1585-95. doi:10.1016/j.jacc.2013.01.047.

14. Kodali S, Pibarot P, Douglas PS, Williams M, Xu K, Thourani V, et al. Paravalvular regurgitation after transcatheter aortic valve replacement with the Edwards sapien valve in the PARTNER trial: characterizing patients and impact on outcomes. Eur Heart J. 2015;36(7):449-56. doi:10.1093/eurheartj/ehu384.

15. Van Bortel LM, Duprez D, Starmans-Kool MJ, Safar ME, Giannattasio C, Cockcroft J, et al. Clinical applications of arterial stiffness, task force III: recommendations for user procedures. Am J Hypertens. 2002;15(5):445-52. doi:10.1016/s0895-7061(01)02326-3.

16. Franssen PM, Imholz BP. Evaluation of the mobil-o-graph new generation ABPM device using the ESH criteria. Blood Press Monit. 2010;15(4):229-31. doi:10.1097/MBP.0b013e328339be38.

17. Wassentheurer S, Kropf J, Weber T, van der Giet M, Baulmann J, Ammer M, et al. A new oscillometric method for pulse wave analysis: comparison with a common tonometric method. J Hum Hypertens. 2010;24(8):498-504. doi:10.1038/jhh.2010.27.

18. Zamorano JL, Badano LP, Bruce C, Chan KL, Gonçalves A, Hahn RT, et al. EAE/AES recommendations for the use of echocardiography in new transcatheter interventions for valvular heart disease. Eur Heart J. 2011;32(17):2189-214. doi:10.1093/eurheartj/ehr259.

19. Mihara H, Shibayama K, Jilahawii H, Itabashi Y, Berdejo J, Utsunomiya H, et al. Assessment of post-procedural aortic regurgitation after TAVR: an intraprocedural TEE study. JACC Cardiovasc Imaging. 2015;8(9):993-1003. doi:10.1016/j.jcmg.2015.02.029.

20. Sinning JM, Hammerstingl C, Vasa-Nicotera M, Adenauer V, Lema Cachiguango SJ, Scheer AC, et al. Aortic regurgitation index defines severity of peri-prosthetic regurgitation and predicts outcome in patients after transcatheter aortic valve implantation. J Am Coll Cardiol. 2012;59(13):1134-41. doi:10.1016/j.jacc.2011.11.048.

21. Ni Y, Wang H, Hu D, Zhang W. The relationship between pulse wave velocity and pulse pressure in Chinese patients with essential hypertension. Hypertens Res. 2003;26(11):871-4. doi:10.1291/hypres.26.871.

22. Chahine J, Kadri AN, Gajulapalli RD, Krishnaswamy A, Mick S, Perez O, et al. Outcomes of transcatheter aortic valve replacement in mixed aortic valve disease. JACC Cardiovasc Interv. 2019;12(22):2299-306. doi:10.1016/j.jcin.2019.06.020.

23. Stundl A, Lucht H, Shamekhi J, Weber M, Sedaghat A, Mellert F, et al. Early versus newer generation transcatheter heart valves for transcatheter aortic valve implantation: echocardiographic and hemodynamic evaluation of an all-comers study cohort using the dimensionless aortic regurgitation index (AR-index). PLoS One. 2019;14(5):e0217544. doi:10.1371/journal.pone.0217544.

24. Schoechlin S, Brenne mann T, Allali A, Ruile P, Jander N, Allgeier M, et al. Hemodynamic classification of paravalvular leakage after transcatheter aortic valve implantation compared with angiographic or echocardiographic classification for prediction of 1-year mortality. Catheter Cardiovasc Interv. 2018;91(6):E56-63. doi:10.1002/ccd.27384.

25. Takagi H, Umemoto T; ALICE (All-Literature Investigation of Cardiovascular Evidence) Group. Impact of paravalvular aortic regurgitation after transcatheter aortic valve implantation on survival. Int J Cardiol. 2016;221:46-51. doi:10.1016/j.ijcard.2016.07.006.

26. Tamburino C, Capodanno D, Ramondo A, Petronio AS, Ettori F, Santoro G, et al. Incidence and predictors of early and late mortality after transcatheter aortic valve implantation in 663 patients with severe aortic stenosis. Circulation. 2011;123(3):299-308. doi:10.1161/CIRCULATIONAHA.110.946533.

27. Gotzmann M, Lindstaedt M, Mügge A. From pressure overload to volume overload: aortic regurgitation after transcatheter aortic valve implantation. Am Heart J. 2012;163(6):903-11. doi:10.1016/j.ahj.2012.03.017.